{"id":493353,"date":"2026-06-11T00:10:11","date_gmt":"2026-06-11T00:10:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/493353\/"},"modified":"2026-06-11T00:10:11","modified_gmt":"2026-06-11T00:10:11","slug":"75-trastuzumab-deruxtecan-in-her2-low-metastatic-breast-cancer-real-world-treatment-patterns-and-outcomes-from-community-oncology-settings","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/493353\/","title":{"rendered":"75 Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings"},"content":{"rendered":"<p> Background<\/p>\n<p class=\"\">The approval of trastuzumab deruxtecan (T-DXd) has transformed treatment for HER2-low\/ultralow metastatic breast cancer. However, real-world data regarding treatment patterns and effectiveness remains limited, particularly in community settings. This study evaluated T-DXd use and outcomes across US community oncology clinics.<\/p>\n<p>Methods<\/p>\n<p class=\"\">Retrospective study using structured and unstructured electronic health record data from ONCare Alliance. Eligible patients received T-DXd for treatment of HER2-low metastatic breast cancer. Baseline characteristics, overall response rate, and time-to-event outcomes from T-DXd initiation were analyzed with descriptive statistics and Kaplan-Meier methods, using log-rank and chi-square tests of group differences. Results were stratified by hormone receptor (HR) status, prior chemotherapy, and presence of brain metastases.<\/p>\n<p>Results<\/p>\n<p class=\"\">Median age among 300 randomly sampled patients (77.0% HR\u2013positive [HR+]; 23.0% HR-negative [HR\u2013]) was 65 years, and 79.7% were White. One-fourth (24.7%) had de novo metastatic breast cancer, 22.7% had ECOG performance status of 2 or more, and 39.3% had 1 or more comorbidity. Most patients received T-DXd monotherapy (87.3%). Baseline characteristics were similar by HR status, but HR+ patients received T-DXd in later lines (3 lines or more: 88.7% HR+ and 53.6% HR\u2013). Median follow-up was 12.1 months (13.1 months HR+ and 10.0 months HR\u2013). Median real-world progression-free survival (rwPFS) was 7.4 months (7.7 months HR+ and 4.9 months HR\u2013). The 12-month overall survival (OS) was 62% (64% HR+ and 55% HR\u2013). Real-world overall response rate was 56.3% (56.4% HR+ and 56.0% HR\u2013). Among patients who were HR+, T-DXd showed greater effectiveness in HR+ chemotherapy-naive (n = 41) compared with HR+ non-chemotherapy-naive (n = 190): rwPFS was 10.2 vs 7.4 months and 12-month OS was 74% vs 62% (P &lt; .05 for both). rwPFS was numerically similar in patients with brain metastases (n = 40) vs those without (n = 260): 6.3 vs 7.5 months (P = .07) (Table).<\/p>\n<p>Conclusions<\/p>\n<p class=\"\">T-DXd demonstrated favorable effectiveness in real-world community oncology patients with HR+ and HR\u2013 HER2-low mBC, despite this population appearing older, frailer, and more heavily pretreated than typical clinical trial patients. These findings support the use of T-DXd across diverse clinical settings.<\/p>\n","protected":false},"excerpt":{"rendered":"Background The approval of trastuzumab deruxtecan (T-DXd) has transformed treatment for HER2-low\/ultralow metastatic breast cancer. However, real-world data&hellip;\n","protected":false},"author":2,"featured_media":422481,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-493353","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/493353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=493353"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/493353\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/422481"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=493353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=493353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=493353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}